Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | MTOR | P42345 | 1/20 | 0.69 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.69 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.69 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.69 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608348 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11617377 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10177274 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2212574 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18151989 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4735554 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL28151155 | 0.96 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2537576 | 0.92 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11327207 | 0.92 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL39903 | 0.92 | P2RY2 (0.58) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4679087-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| US-20250333730-A1 | SIRNA FOR INHIBITING ANGPTL3 GENE EXPRESSION AND USE THEREOF | SHANGHAI JUNSHI BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | claimed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | claimed |
| US-20250250573-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SIRIUS THERAPEUTICS, INC. | 2025-08-07 | — | — | US | claimed |
| EP-4594484-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| EP-4569114-A2 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| EP-4568682-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| US-20250188465-A1 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | SIRIUS THERAPEUTICS, INC. | 2025-06-12 | — | — | US | claimed |
| US-20250188464-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SIRIUS THERAPEUTICS, INC. | 2025-06-12 | — | — | US | claimed |
| CN-120076811-A | Polynucleic acid molecules, pharmaceutical compositions and uses thereof for inhibiting the expression of Lp (a) | 靖因药业有限公司 | 2025-05-30 | — | — | CN | claimed |
| WO-2022266753-A1 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-12-29 | — | — | WO | claimed |
| WO-2022268054-A1 | SIRNA INHIBITING ANGPTL3 GENE EXPRESSION, AND USE THEREOF | 上海君实生物医药科技股份有限公司 | 2022-12-29 | — | — | WO | claimed |
| CN-113624862-A | Metabolome covering multiple metabolites, metabolic flux analysis method and kit | 清华大学 | 2021-11-09 | — | — | CN | claimed |
| EP-1501938-B1 | ANALYSIS OF SUBSTRATE UTILIZATION BY ANIMAL OR PLANT CELLS | BIOLOG INC (US) | 2009-10-21 | — | — | EP | claimed |
| EP-1501938-A4 | COMPARATIVE PHENOTYPE ANALYSIS OF CELLS, INCLUDING TESTING OF BIOLOGICALLY ACTIVE COMPOUNDS | BIOLOG INC (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1501938-A2 | COMPARATIVE PHENOTYPE ANALYSIS OF CELLS, INCLUDING TESTING OF BIOLOGICALLY ACTIVE COMPOUNDS | BIOLOG, INC. (US) | 2005-02-02 | — | — | EP | claimed |
| US-6727076-B2 | UTILIZES A GEL FORMING MATRIX FOR THE RAPID SCREENING OF CLINICAL AND ENVIRONMENTAL CULTURES | BIOLOG, INC. | 2004-04-27 | — | — | US | claimed |
| WO-2003089652-A2 | COMPARATIVE PHENOTYPE ANALYSIS OF CELLS, INCLUDING TESTING OF BIOLOGICALLY ACTIVE COMPOUNDS | BIOLOG, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20030162164-A1 | Comparative phenotype analysis of cells, including testing of biologically active compounds | BIOLOG, INC. | 2003-08-28 | — | — | US | claimed |
| US-6472201-B1 | GROWING AND TESTING MICROORGANISMS IN A MULTITEST FORMAT WHICH UTILIZES A GEL FORMING MATRIX FOR THE RAPID SCREENING OF CLINICAL AND ENVIRONMENTAL CULTURES | BIOLOG, INC. | 2002-10-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333730-A1 | SIRNA FOR INHIBITING ANGPTL3 GENE EXPRESSION AND USE THEREOF | TEK, TIE1, PCSK9 | LMNA 1942/4885THRB 2493/4885MTOR 3980/4885 |
| US-20250188464-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LPL, LDLR, PNLIP | LMNA 11/4885THRB 2542/4885MTOR 4778/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | LMNA 240/4885THRB 4546/4885MTOR 3099/4885 |
| US-20250250573-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | F13B, F13A1, F12 | LMNA 350/4885THRB 2024/4885MTOR 4795/4885 |
| US-20250188465-A1 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | APOB, APOL1, NOP10 | LMNA 114/4885THRB 2740/4885MTOR 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.